Gadolinium and nephrogenic systemic fibrosis: have the alarm bells been silenced?
We review the current approach to using gadoliniumbased contrast agents taking into account data published in the literature and US Food and Drug Administration and European Medicines Evaluation Agency (EMEA) guidelines.